Aktis Oncology, Inc. Common stock (AKTS)
Who owns Aktis Oncology, Inc. Common stock (AKTS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 52.7% of the shares are freely tradable; institutional investors hold 74.2%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| MPM Oncology Impact Management LP | 8.75 | 4,835,872 | +0.0 | 03/31/2026 |
| EcoR1 Capital, LLC | 8.73 | 4,824,469 | +0.0 | 03/31/2026 |
| Blue Owl Capital Holdings LP | 5.72 | 3,161,348 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 4.19 | 2,317,044 | +0.0 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 3.84 | 2,123,812 | +0.0 | 03/31/2026 |
| BlackRock Inc | 3.82 | 2,112,127 | +0.0 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 2.88 | 1,592,043 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 2.83 | 1,564,196 | +0.0 | 03/31/2026 |
| RA Capital Management, LLC | 2.72 | 1,503,084 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Health Care Inv | 3.66 | 2,023,644 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Jul 2026 | Herrmann Ken | Director | Sell | 1,350 | 24.56 | 33,159 |
| 20. Jul 2026 | Herrmann Ken | Director | Sell | 3,506 | 24.56 | 86,115 |
| 20. Jul 2026 | Herrmann Ken | Director | Other | 1,350 | 1.91 | 2,579 |
| 20. Jul 2026 | Herrmann Ken | Director | Other | 3,506 | 0.08 | 280 |
| 17. Jul 2026 | Herrmann Ken | Director | Sell | 3,065 | 25.21 | 77,259 |
| 17. Jul 2026 | Herrmann Ken | Director | Other | 3,065 | 0.08 | 245 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.